# Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

> **NCT04404088** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Ann Arbor Stage III Grade 3 Follicular Lymphoma
- Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Ann Arbor Stage IV Grade 2 Follicular Lymphoma
- Ann Arbor Stage IV Grade 3 Follicular Lymphoma
- Grade 3a Follicular Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT04404088
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-16
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404088, "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT04404088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*